Drug Profile
LY 2452473/tadalafil
Alternative Names: LY 900010; LY2452473/tadalafil; tadalafil/LY 2452473Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Carbolines; Erectile dysfunction therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Erectile dysfunction
Most Recent Events
- 18 Apr 2012 Discontinued - Phase-II for Erectile dysfunction in USA (PO)
- 30 Nov 2011 Eli Lilly completes a phase II trial in Erectile dysfunction in USA (NCT01160289)
- 12 Sep 2011 Eli Lilly completes a phase I trial in Healthy volunteers in US (NCT01401543)